Molecular Subtype
HER2-Positive Breast Carcinoma
CI-CAN-00007795Explore in graph →
140 active trials3 approved drugs93 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007795Explore in graph →
Clinical trials
377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02060253 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer(STEFNE) | terminated | Phase 1 / Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 24, 2018 |
| NCT00194779 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | terminated | Phase 1 / Phase 2 | 4 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01688609 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2017 | clinicaltrials |
| NCT02135159 | Patients With Brain Metastases From HER2-positive Breast Cancer(BIRTH) | completed | Phase 1 | 36 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT03085368 | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin | unknown | Phase 2 / Phase 3 | 482 | Peking Union Medical College HospitalOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00331552 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00791037 | Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00079326 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00077376 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT01329640 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | terminated | Phase 2 | 9 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy(DAFNE) | completed | Phase 2 | 65 | GBG Forschungs GmbHOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00006228 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00003440 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | completed | Phase 3 | 580 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer | withdrawn | Phase 1 | 0 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00039455 | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | terminated | Phase 2 | 29 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 11, 2012 | clinicaltrials |
| NCT01100489 | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2018source: clinicaltrials